Kevin D Burns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3105230/publications.pdf

Version: 2024-02-01

66 papers

2,752 citations

393982 19 h-index 51 g-index

67 all docs

67 docs citations

67 times ranked

4888 citing authors

#	Article	IF	CITATIONS
1	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
2	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
3	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
4	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and TreatmentÂof Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
5	Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury. American Journal of Pathology, 2015, 185, 2309-2323.	1.9	186
6	Transfer of microRNA-486-5p from human endothelial colony forming cell–derived exosomes reduces ischemic kidney injury. Kidney International, 2016, 90, 1238-1250.	2.6	177
7	Urinary Podocyte Microparticles Identify Prealbuminuric Diabetic Glomerular Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 1401-1407.	3.0	117
8	Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney International, 2014, 86, 1057-1058.	2.6	93
9	High glucose increases the formation and pro-oxidative activity of endothelial microparticles. Diabetologia, 2017, 60, 1791-1800.	2.9	79
10	Receptor-Ligand Interaction Mediates Targeting of Endothelial Colony Forming Cell-derived Exosomes to the Kidney after Ischemic Injury. Scientific Reports, 2018, 8, 16320.	1.6	65
11	Characterization of Angiotensin-Converting Enzyme 2 Ectodomain Shedding from Mouse Proximal Tubular Cells. PLoS ONE, 2014, 9, e85958.	1.1	51
12	The emerging role of angiotensin-converting enzyme-2 in the kidney. Current Opinion in Nephrology and Hypertension, 2007, 16, 116-121.	1.0	33
13	The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 312, F335-F342.	1.3	33
14	Differential renal effects of candesartan at high and ultra-high doses in diabetic mice–potential role of the ACE2/AT2R/Mas axis. Bioscience Reports, 2016, 36, .	1.1	32
15	Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2). Methods in Molecular Biology, 2017, 1527, 101-115.	0.4	32
16	The role of angiotensin II-stimulated renal tubular transport in hypertension. Current Hypertension Reports, 2003, 5, 165-171.	1.5	28
17	PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes. Diabetologia, 2016, 59, 1318-1328.	2.9	28
18	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.4	23

#	Article	IF	CITATIONS
19	PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct. Laboratory Investigation, 2018, 98, 360-370.	1.7	22
20	Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. Diabetes Care, 2021, 44, e45-e47.	4.3	22
21	Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2021, 77, 178-189.e1.	2.1	21
22	Sex diversity in proximal tubule and endothelial gene expression in mice with ischemic acute kidney injury. Clinical Science, 2020, 134, 1887-1909.	1.8	21
23	C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0127439.	1.1	19
24	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. Canadian Journal of Diabetes, 2021, 45, 162-166.e1.	0.4	19
25	The Effect of Angiotensin-(1-7) in Mouse Unilateral Ureteral Obstruction. American Journal of Pathology, 2015, 185, 729-740.	1.9	18
26	Alpha-Blocker Use and the Risk of Hypotension and Hypotension-Related Clinical Events in Women of Advanced Age. Hypertension, 2019, 74, 645-651.	1.3	18
27	Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. PLoS ONE, 2014, 9, e97135.	1.1	16
28	Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors. Laboratory Investigation, 2015, 95, 1044-1055.	1.7	15
29	Protein Kinase C-δ Mediates Shedding of Angiotensin-Converting Enzyme 2 from Proximal Tubular Cells. Frontiers in Pharmacology, 2016, 7, 146.	1.6	14
30	micro-RNA-486-5p protects against kidney ischemic injury and modifies the apoptotic transcriptome in proximal tubules. Kidney International, 2021, 100, 597-612.	2.6	14
31	Urinary angiotensinogen as a biomarker of chronic kidney disease: ready for prime time?. Nephrology Dialysis Transplantation, 2012, 27, 3010-3013.	0.4	13
32	Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease. American Journal of Nephrology, 2019, 49, 328-330.	1.4	13
33	Performance of the 2021 Race-Free CKD-EPI Creatinine-Âand Cystatin C–Based Estimated GFR Equations Among Kidney Transplant Recipients. American Journal of Kidney Diseases, 2022, 80, 462-472.e1.	2.1	13
34	Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease. Kidney International Reports, 2018, 3, 691-700.	0.4	12
35	The association of urinary sodium excretion and the need for renal replacement therapy in advanced chronic kidney disease: a cohort study. BMC Nephrology, 2016, 17, 123.	0.8	11
36	Changes in Body Weight Before and After Kidney Donation. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811984720.	0.6	11

#	Article	IF	CITATIONS
37	Prostaglandin E2 receptor EP1 (PGE2/EP1) deletion promotes glomerular podocyte and endothelial cell injury in hypertensive TTRhRen mice. Laboratory Investigation, 2020, 100, 414-425.	1.7	11
38	miRNA-486-5p: signaling targets and role in non-malignant disease. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	11
39	Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. JAMA Network Open, 2021, 4, e2123365.	2.8	10
40	Circulating Angiogenic Factors in a Pregnant Woman on Intensive Hemodialysis: A Case Report. Canadian Journal of Kidney Health and Disease, 2016, 3, 96.	0.6	9
41	Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging. PLoS ONE, 2017, 12, e0177451.	1.1	8
42	The KRESCENT Program: An initiative to match supply and demand for kidney research in Canada. Clinical and Investigative Medicine, 2010, 33, 356.	0.3	8
43	Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease. Canadian Journal of Cardiology, 2017, 33, 611-618.	0.8	7
44	An evaluation of reninâ€angiotensin system markers in youth with type 2 diabetes and associations with renal outcomes. Pediatric Diabetes, 2020, 21, 1102-1109.	1.2	7
45	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
46	Comparative analysis of hypertensive nephrosclerosis in animal models of hypertension and its relevance to human pathology. Glomerulopathy. PLoS ONE, 2022, 17, e0264136.	1.1	7
47	The impact of intervention strategies that target arterial stiffness in end-stage renal disease: a systematic review protocol. Systematic Reviews, 2016, 5, 118.	2.5	6
48	The therapeutic effects of microRNAs in preclinical studies of acute kidney injury: a systematic review protocol. Systematic Reviews, 2019, 8, 235.	2.5	6
49	A Systematic Review and Meta-analysis ofÂNonpharmacologic-based Interventions for Aortic Stiffness in End-Stage Renal Disease. Kidney International Reports, 2019, 4, 1109-1121.	0.4	6
50	A novel method for comparison of arterial remodeling in hypertension: Quantification of arterial trees and recognition of remodeling patterns on histological sections. PLoS ONE, 2019, 14, e0216734.	1.1	6
51	Pharmacologic Therapies for Aortic Stiffness in End-Stage Renal Disease: A Systematic Review and Meta-Analysis. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812090697.	0.6	6
52	Therapeutic effects of micro-RNAs in preclinical studies of acute kidney injury: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 9100.	1.6	6
53	Reproducibility of Carotid-Femoral Pulse Wave Velocity in End-Stage Renal Disease Patients: Methodological Considerations. Canadian Journal of Kidney Health and Disease, 2016, 3, 109.	0.6	5
54	Renovascular hypertension from the BCRâ€ABL tyrosine kinase inhibitor ponatinib. Journal of Clinical Hypertension, 2020, 22, 678-682.	1.0	5

#	Article	IF	Citations
55	Pincer nails following arteriovenous fistula creation. Kidney International, 2015, 88, 918.	2.6	4
56	The KRESCENT Program (2005-2015). Canadian Journal of Kidney Health and Disease, 2017, 4, 205435811769335.	0.6	4
57	Isolated Penile Calciphylaxis Diagnosed by Ultrasound Imaging in a New Dialysis Patient: A Case Report. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110258.	0.6	3
58	The impact of measuring split kidney function on post-donation kidney function: A retrospective cohort study. PLoS ONE, 2021, 16, e0253609.	1.1	3
59	Renal Hemodynamics and Renin-Angiotensin-Aldosterone System Profiles in Patients With Heart Failure. Journal of Cardiac Failure, 2021, , .	0.7	3
60	A Unique Case of Metformin-Associated Lactic Acidosis. Case Reports in Nephrology, 2018, 2018, 1-5.	0.2	2
61	Effects of living kidney donation on arterial stiffness: a systematic review protocol. BMJ Open, 2021, 11, e045518.	0.8	2
62	Cannabis and Cigarette Use Before and After Living Kidney Donation. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812199724.	0.6	2
63	Re: Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney International, 2015, 88, 915.	2.6	1
64	MicroRNA in Human Acute Kidney Injury: A Systematic Review Protocol. Canadian Journal of Kidney Health and Disease, 2021, 8, 205435812110099.	0.6	1
65	Case Report: Segmental Arterial Mediolysis, a Rare Cause of Hypertension. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812095088.	0.6	O
66	Brief ACE Inhibition Produces Persistent Changes That Protect Heart but Not Kidney From Lâ€NAME Induced Damage. FASEB Journal, 2009, 23, 1017.44.	0.2	0